FORT LEE, N.J. — November 4, 2025 — Leads & Copy — Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported its Q3 2025 financial results and provided a business progress update, including the initiation of the NXP900 Phase 1b program, dose escalation study, and drug-drug interaction study. The cash runway is expected to support operations into Q3 2027.
Chairman and CEO Ron Bentsur highlighted the focus on advancing the clinical work for NXP900’s Phase 1b program, with the goal of showcasing its therapeutic potential as a single agent and in combination with market-leading therapies to reverse acquired resistance.
As of September 30, 2025, cash and cash equivalents totaled $35.4 million, compared to $18.5 million on December 31, 2024. The company’s net loss for the three months ended September 30, 2025, was $7.5 million, compared to $4.2 million for the three months ended September 30, 2024.
Research and development expenses were $5.8 million for the three months ended September 30, 2025, compared to $2.8 million for the three months ended September 30, 2024. General and administrative expenses were $2.0 million for the three months ended September 30, 2025, compared to $1.5 million for the three months ended September 30, 2024. Interest income was $0.3 million for the three months ended September 30, 2025, compared to $0.2 million for the three months ended September 30, 2024.
Nuvectis Pharma, Inc. is focused on developing innovative precision medicines for oncology, with its lead program, NXP900, in Phase 1b evaluation.
Ron Bentsur, Chairman and Chief Executive Officer, rbentsur@nuvectis.com
Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com
Source: Nuvectis Pharma, Inc.
